Ebola Raises Questions On Incentives For Drug, Vaccine Research
TIME: Ebola Should Change How We Fund Drugs for Emerging Disease
“Emerging and infectious diseases are having a moment for all the worst reasons, with credit due to the Ebola outbreak. But scientists studying other emerging diseases beyond Ebola are hopeful that the attention on the disease — and what can happen without available therapeutics — is here to stay. The fact that there are no drugs or vaccines approved for Ebola isn’t for a dearth of research, but rather because there’s scant financial incentive for pharmaceutical companies to take on the treatments…” (Sifferlin, 10/8).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.